MagicMed Industries aims to become a leader in the development of patentable psychedelic molecular derivatives. The company aims to license these molecular derivatives to pharmaceutical and consumer goods companies to generate attractive, high-margin recurring revenue for their shareholders.

Proven team that has previously developed opiate and cannabinoid programs with large partners.

Entire current management and science team is financially invested in the company's success.

Relationships with established pharmaceutical and CPG manufacturers will be built upon over time.

Deep science and business expertise enables rapid PsybraryTM expansion to a brand range of derivatives. 

Controlled cost structure with sustainable near-term revenue via milestone based compensation model.

Royalty sharing opens the door to participating in potential long-term Big Pharma market revenue.

CEO

Dr. Tucker is a seasoned executive who has built several publicly-traded biotech companies and has worked with MagicMed's science team since 2013.

COO

Dr. Hagel previously held COO and VP roles in the biotech industry with a focus on science team coordination and patent filings.

CSO

Dr. Facchini has been CSO eat several public and private biotech companies and is a recognized leader in the development of new molecular derivatives.